The emerging treatment landscape for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has resulted in improved outcomes for patients. However, challenges remain when selecting the best frontline approach and now involve decisions about using a time-limited option or continued therapy model. Other challenges exist on relapse, so it’s essential that providers understand the disease and patient factors that are critical when sequencing therapeutic agents. Join us in this Streaming National Broadcast that will help you meet the treatment needs of your patients with CLL/SLL both today and in the future.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Individualized Approaches in CLL/SLL: Meeting the Needs of Your Patients Now and Preparing for the Future
Outcomes are improving for patients with CLL/SLL. But how confident are you when selecting initial/sequential therapies or a time-limited option?
Live
Broadcast
1.00 available credits
Information
December 21, 2022
12:00 PM - 01:00 PM EST
Share this program on:
Details
Presenters
Related
Comments
Overview
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Andrew H. Lipsky, MD
Associate Professor of Medicine
Columbia University Medical Center
Herbert Irving Comprehensive Care Center
New York, NYConsulting Fees: AbbVie, AstraZeneca
Faculty:
Catherine C. Coombs, MD
Associate Clinical Professor
University of California, Irvine
Orange, CAResearch: AbbVie, Loxo@Lilly
Ownership Interest: Bluebird Bio, CTI Biopharma
Consulting Fees: AbbVie, AstraZeneca, BeiGene, Genentech, Janssen, Loxo@Lilly, MEI Pharma, MingSight Pharmaceuticals, Octapharma, TG TherapeuticsJacob D. Soumerai, MD
Assistant Professor of Medicine, Harvard Medical
School, Clinical Investigator in Lymphoma and CLL,
Massachusetts General Hospital Cancer Center
Boston, MAConsulting Fees: AbbVie, AstraZeneca, Verastem Oncology
Research: BeiGene, BostonGene, Genentech/Roche, TG TherapeuticsReviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Stephen Chavez has nothing to disclose.
- Barry A. Fiedel, PhD, has nothing to disclose.
- Colleen Resnick has nothing to disclose.
- Anna Trentini has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Select therapy for individual patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
- Sequence therapies for patients with CLL or SLL
- Manage adverse events associated with treatments for patients with CLL or SLL
- Discuss ongoing clinical trial results of studies in patients with CLL or SLL
- Identify the clinical implications of current and emerging time-limited therapies
Target Audience
This activity is designed to meet the educational needs of hematologists, oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and any other HCPs involved in the treatment of CLL.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Global Learning Collaborative (GLC) designates this Live Broadcast activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hours/0.1 CEUs of Pharmacy contact hours.
The Universal Activity Number for this program is JA-0006235-0000-22-074-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Janssen Scientific Affairs, LLC.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Details
Presenters
Related
Comments
Recommended
Overview
The emerging treatment landscape for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has resulted in improved outcomes for patients. However, challenges remain when selecting the best frontline approach and now involve decisions about using a time-limited option or continued therapy model. Other challenges exist on relapse, so it’s essential that providers understand the disease and patient factors that are critical when sequencing therapeutic agents. Join us in this Streaming National Broadcast that will help you meet the treatment needs of your patients with CLL/SLL both today and in the future.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Andrew H. Lipsky, MD
Associate Professor of Medicine
Columbia University Medical Center
Herbert Irving Comprehensive Care Center
New York, NYConsulting Fees: AbbVie, AstraZeneca
Faculty:
Catherine C. Coombs, MD
Associate Clinical Professor
University of California, Irvine
Orange, CAResearch: AbbVie, Loxo@Lilly
Ownership Interest: Bluebird Bio, CTI Biopharma
Consulting Fees: AbbVie, AstraZeneca, BeiGene, Genentech, Janssen, Loxo@Lilly, MEI Pharma, MingSight Pharmaceuticals, Octapharma, TG TherapeuticsJacob D. Soumerai, MD
Assistant Professor of Medicine, Harvard Medical
School, Clinical Investigator in Lymphoma and CLL,
Massachusetts General Hospital Cancer Center
Boston, MAConsulting Fees: AbbVie, AstraZeneca, Verastem Oncology
Research: BeiGene, BostonGene, Genentech/Roche, TG TherapeuticsReviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Stephen Chavez has nothing to disclose.
- Barry A. Fiedel, PhD, has nothing to disclose.
- Colleen Resnick has nothing to disclose.
- Anna Trentini has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Select therapy for individual patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
- Sequence therapies for patients with CLL or SLL
- Manage adverse events associated with treatments for patients with CLL or SLL
- Discuss ongoing clinical trial results of studies in patients with CLL or SLL
- Identify the clinical implications of current and emerging time-limited therapies
Target Audience
This activity is designed to meet the educational needs of hematologists, oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and any other HCPs involved in the treatment of CLL.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Global Learning Collaborative (GLC) designates this Live Broadcast activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hours/0.1 CEUs of Pharmacy contact hours.
The Universal Activity Number for this program is JA-0006235-0000-22-074-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Janssen Scientific Affairs, LLC.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Facebook Comments